Page last checked
Wegovy vs Ozempic
Wegovy and Ozempic contain semaglutide, but their approved uses and dose schedules differ. The table compares their weekly injections and notes the separate tablet forms.
Source for this answer
Source: Read from both FDA labels on DailyMed
Source: Read from both FDA labels on DailyMed
Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewerReviewed 2026-08-12every number here is sourced
Wegovy and Ozempic, line by line
4 of 11 details match; 7 differ. Compare the approved uses, injection doses and other label details below.
| Question | Wegovy | Ozempic |
|---|---|---|
| What is in itSame on both labels | Semaglutide | Semaglutide |
| Who makes itSame on both labels | Novo Nordisk | Novo Nordisk |
| How oftenSame on both labels | Once a week | Once a week |
| Approved uses | Weight management in eligible adults and adolescents aged 12 and older; heart-risk reduction and certain MASH liver disease in eligible adults | Blood sugar in type 2 diabetes, heart risk reduction in type 2 diabetes, and kidney decline in type 2 diabetes |
| Starting doseSame on both labels | 0.25 mg once a week | 0.25 mg once a week |
| Highest dose | 2.4 mg, or 7.2 mg for weight reduction in adults | 2 mg |
| Maintenance doses | 1.7, 2.4 or 7.2 mg | 0.5, 1 or 2 mg |
| How a missed week is handled | Take it if the next dose is more than 2 days off, otherwise skip | Take it within 5 days, otherwise skip |
| Youngest patient covered | Age 12 | Adults only |
| Is there a pill | Yes, a tablet at 1.5, 4, 9 and 25 mg, under a separate application | Yes. Ozempic tablets have a separate label and dose schedule, shared with Rybelsus |
| What the label reports for nausea | 44 in 100 at 2.4 mg, against 16 on placebo | 20.3 in 100 at 1 mg, against 6.1 on placebo |
Product comparison at a glance
- Wegovy
- Semaglutide
- Ozempic
- Semaglutide
- Label differences
- 7 of 11 comparison rows differ
- Direct trial
- None published
Has anyone tested Wegovy against Ozempic directly?
No direct trial is included in the sources below. The two products contain the same ingredient, but their doses and approved uses can differ.
Both labels draw on trials of semaglutide. Those separate results cannot show which brand works better or causes fewer side effects. Sharing an active drug does not mean the doses or forms can be swapped.
5Comparison details
Why the nausea figures look so far apart
The labels report nausea in 44 of 100 people taking Wegovy 2.4 mg and 20.3 of 100 taking Ozempic 1 mg. Those figures come from separate trials.
The trials used different doses and enrolled different people. Wegovy’s table reports weight-management trials at 2.4 mg; Ozempic’s table reports diabetes trials at up to 1 mg. These figures cannot show which product causes more nausea at a comparable dose.
Both labels open their tables with the warning that rates from one drug’s trials cannot be set against another’s. It applies to this pair even though the drug is the same.
How the injection doses differ
Ozempic stops at 2 mg a week. Wegovy runs to 2.4 mg, and since March 2026 to 7.2 mg for weight reduction in adults.
Wegovy also allows a 1.7 mg maintenance dose for some uses. Ozempic’s 2 mg maximum therefore falls between two Wegovy maintenance doses; it is not a dose-equivalence or switching rule.
Using or switching between the products
The Wegovy label does not recommend using it with another semaglutide product or another GLP-1 receptor agonist. Ozempic contains semaglutide.
The labels do not provide a dose conversion between Wegovy and Ozempic injections. A prescriber needs to plan any switch; the dose difference alone does not establish a starting dose.
What about “Ozempic vs Wegovy”?
Reversing the names does not change the product details or trial results.
Read each result with its own dose, study group and limits, whichever name comes first.
The full label for each
Choose a product below to see its full dose schedule, side effects and storage rules.
Wegovy
Ozempic
Questions readers ask
Can I lose 20 pounds in 3 months on Wegovy?
Can I lose 20 pounds in 3 months on Wegovy?
A 72-week trial average cannot predict a 20-pound loss in three months. At week 12, Wegovy’s standard injection schedule has not reached 2.4 mg.
An average describes the group. It does not mean half lost more and half lost less, and it does not set a deadline for one person.
Which is better for weight loss, Ozempic or Wegovy?
Which is better for weight loss, Ozempic or Wegovy?
Wegovy has an approved weight-management use. Ozempic contains the same drug, semaglutide, but its injection label covers type 2 diabetes and certain heart and kidney uses.
Their dose schedules differ. The weekly injection amounts cannot be used to compare tablet doses, which have separate label instructions.
What is the downside of Wegovy?
What is the downside of Wegovy?
In the label’s adult weight trials, nausea affected 44% on Wegovy 2.4 mg and 16% on placebo. Diarrhea, vomiting and constipation each affected more than 20% on Wegovy.
In the 7.2 mg trials, altered skin sensations affected 22% at 7.2 mg and 6% at 2.4 mg. These figures describe the studied groups, not everyone who uses Wegovy.
Why are people stopping Wegovy?
Why are people stopping Wegovy?
The label reports some people stopping because of side effects. In the adult 2.4 mg weight trials, 6.8% stopped for that reason, versus 3.2% on placebo.
Nausea, vomiting and diarrhea were the most common side effects leading to stopping. These trial findings do not explain every person’s reason for stopping outside a study.
- Wegovy (semaglutide) injection and tablets — FDA-approved Prescribing Information (DailyMed)retrieved 2026-08-12FDA label
- Wegovy (semaglutide) Prescribing Information, revised 06/2026 — Drugs@FDA NDA 215256/S-025retrieved 2026-08-12FDA label
- FDA approval letter, NDA 215256 — Wegovy (semaglutide) injection, chronic weight management in adultsretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 215256/S-005 — Wegovy in pediatric patients aged 12 years and olderretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 215256/S-011 — Wegovy cardiovascular risk reduction indication (SELECT)retrieved 2026-08-12FDA label
- FDA accelerated approval letter, NDA 215256/S-024 — Wegovy for noncirrhotic MASH with stage F2 to F3 fibrosisretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 215256/S-029 — Wegovy injection 7.2 mg once-weekly doseretrieved 2026-08-12FDA label
- FDA approval letter, NDA 218316 — Wegovy (semaglutide) tablets, oral dosage formretrieved 2026-08-12FDA label
- Ozempic (semaglutide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-09-13FDA label
- Drugs@FDA approval history — NDA 209637, Ozempic (semaglutide) injectionretrieved 2026-08-12FDA label
- FDA approval letter, NDA 209637 — Ozempic (semaglutide) injection, glycemic control in adults with type 2 diabetesretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 209637/S-003 — Ozempic cardiovascular event risk reduction in type 2 diabetes with established cardiovascular disease (SUSTAIN 6)retrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 209637/S-025 — Ozempic for reducing sustained eGFR decline, end-stage kidney disease and cardiovascular death in type 2 diabetes with chronic kidney diseaseretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 209637/S-009 — addition of a third Ozempic maintenance dose, 2 mg once weeklyretrieved 2026-08-12FDA label
- RYBELSUS and OZEMPIC (semaglutide) tablets — FDA-approved Prescribing Information (DailyMed SPL), NDA 213051, revised 01/2026retrieved 2026-08-20FDA label